Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced the granting of inducement awards to eight new employees under its 2024 Inducement Plan. The awards, approved by the Compensation Committee, include non-qualified stock options for 99,000 shares and restricted stock units (RSUs) for 48,200 shares of Class A common stock.
The stock options, with an exercise price of $20.45, will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest in 25% increments annually over four years, starting August 20, 2025, contingent on continued employment.
[]Vera Therapeutics (Nasdaq: VERA) ha annunciato la concessione di premi di incentivazione a otto nuovi dipendenti nell'ambito del suo Piano di Induzione 2024. I premi, approvati dal Comitato per la remunerazione, comprendono opzioni su azioni non qualificate per 99.000 azioni e unità di azioni vincolate (RSU) per 48.200 azioni della classe A di azioni ordinarie.
Le opzioni, con un prezzo di esercizio di $20,45, matureranno in quattro anni: il 25% dopo un anno e il restante maturerà mensilmente nei successivi 36 mesi. Le RSU matureranno per il 25% ogni anno per quattro anni, a partire dal 20 agosto 2025, subordinatamente alla prosecuzione del rapporto di lavoro.
Vera Therapeutics (Nasdaq: VERA) anunció la concesión de premios de incentivo a ocho nuevos empleados bajo su Plan de Inducción 2024. Los premios, aprobados por el Comité de Compensación, incluyen opciones sobre acciones no calificadas por 99.000 acciones y unidades de acciones restringidas (RSU) por 48.200 acciones de acciones ordinarias Clase A.
Las opciones, con un precio de ejercicio de $20.45, se consolidarán en cuatro años, con un 25% tras el primer año y el resto devengado mensualmente durante los siguientes 36 meses. Las RSU se consolidarán en tramos del 25% anuales durante cuatro años, a partir del 20 de agosto de 2025, condicionadas a la continuidad en el empleo.
Vera Therapeutics (Nasdaq: VERA)는 2024년 인덕스먼트(Inducement) 플랜에 따라 8명의 신입 직원에게 인센티브 보상을 부여했다고 발표했습니다. 보상안은 보상위원회 승인을 받았으며 99,000주에 대한 비자격(Non‑qualified) 스톡옵션과 48,200주에 대한 제한부 주식단위(RSUs)로 구성되어 있습니다(클래스 A 보통주).
행사가격은 $20.45이며, 스톡옵션은 4년간 베스팅됩니다. 1년 후 25%가 베스트되고 나머지는 향후 36개월 동안 매월 나누어 베스트됩니다. RSU는 2025년 8월 20일부터 시작해 매년 25%씩 4년에 걸쳐 베스트되며, 계속 근무하는 것을 전제로 합니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé l'attribution de récompenses d'incitation à huit nouveaux employés dans le cadre de son Plan d'Inducement 2024. Les attributions, approuvées par le comité de rémunération, comprennent des options d'achat d'actions non qualifiées pour 99 000 actions et des unités d'actions restreintes (RSU) pour 48 200 actions d'actions ordinaires de catégorie A.
Les options, avec un prix d'exercice de $20,45, seront acquises sur quatre ans : 25 % après un an et le reste mensuellement sur les 36 mois suivants. Les RSU seront acquises à hauteur de 25 % par an sur quatre ans, à partir du 20 août 2025, sous réserve de la continuité de l'emploi.
Vera Therapeutics (Nasdaq: VERA) hat die Gewährung von Anreizzuteilungen an acht neue Mitarbeiter im Rahmen seines Inducement-Plans 2024 bekannt gegeben. Die Zuteilungen, die vom Vergütungsausschuss genehmigt wurden, umfassen nicht qualifizierte Aktienoptionen für 99.000 Aktien sowie Restricted Stock Units (RSUs) für 48.200 Aktien der Class‑A‑Stammaktien.
Die Optionen haben einen Ausübungspreis von $20,45 und werden über vier Jahre vesten: 25 % nach einem Jahr und der Rest monatlich über die folgenden 36 Monate. Die RSUs werden zu je 25 % jährlich über vier Jahre vesten, beginnend am 20. August 2025, vorbehaltlich der fortgesetzten Beschäftigung.
- None.
- None.
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on August 4, 2025 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ
What inducement awards did Vera Therapeutics (VERA) grant to new employees in August 2025?
What is the vesting schedule for Vera Therapeutics' (VERA) August 2025 stock option grants?
How will the RSUs granted by Vera Therapeutics (VERA) in August 2025 vest?
What was the exercise price for Vera Therapeutics' (VERA) August 2025 stock option grants?
